查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553705

急性淋巴性白血病治疗市场规模、份额和趋势分析报告：按产品、化疗、应用、年龄组、性别、最终用途、地区和细分趋势：2024-2030

Acute Lymphocytic Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Product, By Chemotherapy, By Application, By Age Group, By Gender, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

急性淋巴性白血病治疗市场成长与趋势

Grand View Research, Inc.的最新报告显示，到2030年，全球急性淋巴性白血病治疗市场规模预计将达到49.9亿美元。

预计2024年至2030年该市场将以7.0%的复合年增长率成长。急性淋巴性白血病 (ALL) 诊断的公共和私人倡议的增加、骨髓切片检查数量的增加以及其他治疗方案的可用性预计将增加 ALL 治疗的采用率。例如，联合国儿童基金会（英国）的婴儿友善倡议计划和加拿大医院与医疗保健提供者之间的合作方式 SickKids-Caribbean Initiative 为符合某些合格标准的患有 ALL 的婴幼儿提供免费诊断。服务。

此外，ALL 发生率的上升预计将提振市场。此病多发于5岁以下儿童。 0 至 20 岁之间患 ALL 的风险最高。然而，成年人也有罹患这种疾病的风险。被诊断出患有这种疾病的男性平均年龄约为 55 岁。

急性淋巴性白血病治疗市场报告亮点

  • 2023 年，化疗占最大的市场收益占有率，达到 39.9%。化疗已在治疗 ALL 方面取得了成功，并实现了高缓解率和长期存活率。
  • 2023年，前驱B细胞急性淋巴性白血病细分市场占40.4%的市场占有率。近年来，随着诊断技术的进步，使该疾病的识别变得更加容易，前体 B 细胞急性淋巴性白血病(ALL) 的发生率一直在上升。
  • 2023年，儿科（0-18岁）细分市场占63.9%的市场占有率。急性淋巴性白血病是儿童最常见的癌症，约占所有儿童癌症的 25%。
  • 到 2023 年，男性细分市场将占据 57.1%的市场占有率，而女性细分市场预计在预测期内复合年增长率为 6.7%。
  • 2023年北美急性淋巴性白血病治疗占主导地位，份额为37.6%。美国的急性淋巴性白血病治疗在北美市场占据主导地位，2023年份额为89.3%。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章急性淋巴性白血病治疗市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 急性淋巴性白血病治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章急性淋巴性白血病治疗市场：依产品估计与趋势分析

  • 细分仪表板
  • 急性淋巴性白血病治疗市场：2023 年和 2030 年产品变化分析
  • 化疗
  • 标靶治疗
  • 放射治疗
  • 干细胞移植

第五章急性淋巴性白血病治疗市场：按应用、估计和趋势分析

  • 细分仪表板
  • 急性淋巴性白血病治疗市场：2023 年和 2030 年应用变化分析
  • 费城染色体
  • 前体B细胞ALL
  • T细胞ALL

第六章急性淋巴性白血病治疗市场：依年龄组别估计及趋势分析

  • 细分仪表板
  • 急性淋巴性白血病治疗市场：2023 年和 2030 年年龄组变化分析
  • 婴儿（0-18岁）
  • 成人（19岁以上）

第七章急性淋巴性白血病治疗市场：性别、估计与趋势分析

  • 细分仪表板
  • 急性淋巴性白血病治疗市场：性别差异分析，2023 年和 2030 年
  • 男性
  • 女士

第八章急性淋巴性白血病治疗市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 急性淋巴性白血病治疗市场：2023 年和 2030 年最终用途变化分析
  • 医院/诊所
  • 癌症护理中心
  • 研究/学术机构

第 9 章急性淋巴性白血病治疗市场：区域、估计和趋势分析

  • 2023年及2030年急性淋巴性白血病治疗市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Bristol-Myer Squibb Company
    • Celegene Corporation
    • Eisai Co., Ltd.
    • Erytech Pharma
    • F. Hoffmann-La Roche Ltd
    • Genmab A/S
    • GSK plc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
简介目录
Product Code: GVR-1-68038-645-5

Acute Lymphocytic Leukemia Therapeutics Market Growth & Trends:

The global acute lymphocytic leukemia therapeutics market size is anticipated to reach USD 4.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.0% from 2024 to 2030. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Acute Lymphocytic Leukemia Therapeutics Market Report Highlights:

  • Chemotherapy accounted for the largest market revenue share of 39.9% in 2023. Chemotherapy has shown success in the treatment of ALL by achieving high rates of remission and long-term survival.
  • The precursor B-cell acute lymphocytic leukemia segment accounted for the market share of 40.4% in 2023. The incidence of precursor B-cell ALL has been increasing in recent years due to several factors such as improvements in diagnostic techniques, which have led to better identification of the disease.
  • The children (0-18) segment accounted for the market share of 63.9% in 2023. Acute lymphocytic leukemia is the most common type of cancer in children, accounting for about 25% of all childhood cancers.
  • The male segment accounted for the market share of 57.1% in 2023 and the female segment is expected to register a CAGR of 6.7% during the forecast period.
  • North America acute lymphocytic leukemia therapeutics held a dominant position with a share of 37.6% in 2023. The U.S. acute lymphocytic leukemia therapeutics dominated the North America market with a share of 89.3% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Acute Lymphocytic Leukemia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Acute Lymphocytic Leukemia Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Acute Lymphocytic Leukemia Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Acute Lymphocytic Leukemia Therapeutics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Hyper-CVAD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. CALGB 8811 Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Linker Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Nucleoside Metabolic Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Oncaspar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Stem Cell Transplantation
    • 4.6.1. Stem Cell Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acute Lymphocytic Leukemia Therapeutics Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Acute Lymphocytic Leukemia Therapeutics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Philadelphia Chromosome
    • 5.3.1. Philadelphia Chromosome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Precursor B-cell ALL
    • 5.4.1. Precursor B-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. T-cell ALL
    • 5.5.1. T-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Children (0-18)
    • 6.3.1. Children (0-18) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Adults (19 +)
    • 6.4.1. Adults (19 +) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acute Lymphocytic Leukemia Therapeutics Market: Gender Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Acute Lymphocytic Leukemia Therapeutics Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Male
    • 7.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Female
    • 7.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acute Lymphocytic Leukemia Therapeutics Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Acute Lymphocytic Leukemia Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 8.3. Hospitals & Clinics
    • 8.3.1. Hospitals & clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Cancer Care Centers
    • 8.4.1. Cancer Care Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Research and academic institutes
    • 8.5.1. Research and Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Acute Lymphocytic Leukemia Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Acute Lymphocytic Leukemia Therapeutics Market Share, By Region, 2023 & 2030, USD Million
  • 9.2. North America
    • 9.2.1. North America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. China Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Japan Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Australia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Saudi Arabia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. Bristol-Myer Squibb Company
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. Celegene Corporation
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Eisai Co., Ltd.
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Erytech Pharma
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. F. Hoffmann-La Roche Ltd
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Genmab A/S
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. GSK plc.
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Novartis AG
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives
    • 10.4.9. Pfizer Inc.
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments/ Strategic Initiatives
    • 10.4.10. Sanofi
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments/ Strategic Initiatives